The impact of metabolic syndrome on metabolic, proinflammatory and prothrombotic markers according to the presence of high blood pressure criterion

Clinics

Volumn 68, Issue 12, 2013, Pages 1495-1501

  Gil, Juliana S ^a   Drager, Luciano F ^a   Guerra Riccio, Grazia M ^a   Mostarda, Cristiano ^a   Irigoyen, Maria C ^a   Costa Hong, Valeria ^a   Bortolotto, Luiz A ^a   Egan, Brent M ^b   Lopes, Heno F ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSIDADE NOVE DE JULHO   (Brazil)

Author keywords

Hypertension; Inflammation; Insulin resistance; Metabolic syndrome; Prothrombosis; Sympathetic activity

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; EVALUATION STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL; THROMBOSIS;

ADULT; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CYTOKINES; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; RISK FACTORS; THROMBOSIS;

EID: 84892756101     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(12)04     Document Type: Article

References (45)

1. Reaven GM., Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607, http://dx.doi.org/10.2337/diab.37.12.1595.
2. Smith S, Julius S, Jamerson K, Amerena J, Schork N. Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. J Hypertens. 1994;12(4):455-62.
3. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1Pt 2):3S-10S.
4. Houston MC. New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach. Am Heart J. 1992;123(5):1337-67, http://dx.doi.org/10.1016/0002-8703(92)91042-Y.
5. Chapman N, Chen CY, Fujita T, Hobbs FD, Kim SJ, Staessen JA, et al Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens. 2010;28:1796-803. Erratum in: J Hypertens. 2010;28(11):2351.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
7. Pimentel GD, Bernhard AB, Frezza MR, Rinaldi AE, Burini RC. Bioelectric impedance overestimates the body fat in overweight and underestimates in Brazilian obese women: a comparison with Segal equation 1. Nutr Hosp. 2010;25(5):741-5.
8. Schipper HS, de Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA, et al. Clin Chem. 2010;56(8):1320-8, http://dx.doi.org/10.1373/clinchem.2010.146118.
9. Drager LF, Ueno LM, Lessa PS, Negrão CE, Lorenzi-Filho G, Krieger EM. Sleep-related changes in hemodynamic and autonomic regulation in human hypertension. J Hypertens. 2009;27(8):1655-63, http://dx.doi.org/10.1097/HJH.0b013e32832c6982.
10. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res. 1986;59(2):178-93, http://dx.doi.org/10.1161/01.RES.59.2.178.
11. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-65.
12. Lucini D, Cusumano G, Bellia A, Kozakova M, Difede G, Lauro R, et al. Is reduced baroreflex gain a component of the metabolic syndrome? Insights from the LINOSA study. J Hypertens. 2006;24(2):361-70, http://dx.doi.org/10.1097/01.hjh.0000202817.02836.9c.
13. Pagani M, Somers V, Furlan R, Dell'Orto S, Conway J, Baselli G, et al. Changes in autonomic regulation induced by physical training in mild hypertension. Hypertension. 1988;12(6):600-10, http://dx.doi.org/10.1161/01.HYP.12.6.600.
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5.
15. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61-8, http://dx.doi.org/10.1016/0165-0327(88)90072-9.
16. Gomes-Oliveira MH, Gorenstein C, Lotufo Neto F, Andrade LH, Wang YP. Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. Rev. Bras. Psiquiatr. 2012;34(4):389-94, http://dx.doi.org/10.1016/j.rbp.2012.03.005.
17. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552-63.
18. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95, http://dx.doi.org/10.2337/diacare.27.6.1487.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin RA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404.
20. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79(3):379-84.
21. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311(6998):158-61, http://dx.doi.org/10.1136/bmj.311.6998.158.
22. Costa GB, Horta N, Resende ZF, Souza G, Barreto LM, Correia LH, et al. Body mass index has a good correlation with proatherosclerotic profile in children and adolescents. Arq Bras Cardiol. 2009;93(3):261-7, http://dx.doi.org/10.1590/S0066-782X2009000900010.
23. Katzmarzyk PT, Srinivasan SR, Chen W, Malina RM, Bouchard C, Berenson GS. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics. 2004;114(2):e198-205, http://dx.doi.org/10.1542/peds.114.2.e198.
24. Schneider HJ, Glaesmer H, Klotsche J, Bohler S, Lehnert H, Zeiher AM, et al. J Clin Endocrinol Metab. 2007;92(2):589-94.
25. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640-9, http://dx.doi.org/10.1016/S0140-6736(05)67663-5.
26. Lambert EA, Lambert GW. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Curr Hypertens Rep. 2011;13(3):244-8, http://dx.doi.org/10.1007/s11906-011-0186-y.
27. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33(5):386-93, http://dx.doi.org/10.1038/hr.2010.9.
28. Flaa A, Aksnes TA, Kjeldsen SE, Eide I, Rostrup M. Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism. 2008;57(10):1422-7, http://dx.doi.org/10.1016/j.metabol.2008.05.012.
29. Jamerson KA, Nesbitt SD, Amerena JV, Grant E, Julius S. Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Hypertension. 1996;27(4):854-8, http://dx.doi.org/10.1161/01.HYP.27.4.854.
30. Jamerson KA, Smith SD, Amerena JV, Grant E, Julius S. Vasoconstriction with norepinephrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction. Hypertension. 1994;23(6 Pt 2):1006-11, http://dx.doi.org/10.1161/01.HYP.23.6.1006.
31. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31(7):415-20, http://dx.doi.org/10.1007/BF00271585.
32. Licht CM, Vreeburg SA, van Reedt Dortland AK, Giltay EJ, Hoogendijk WJ, DeRijk RH, et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab. 2010;95(5):2458-66, http://dx.doi.org/10.1210/jc.2009-2801.
33. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5, http://dx.doi.org/10.1210/jc.86.5.1930.
34. Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, et al. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens. 2010;28(3):543-50, http://dx.doi.org/10.1097/HJH.0b013e3283350ea4.
35. Wirtz PH, Ehlert U, Bartschi C, Redwine LS, von Kanel R. Changes in plasma lipids with psychosocial stress are related to hypertension status and the norepinephrine stress response. Metabolism. 2009;58(1):30-7, http://dx.doi.org/10.1016/j.metabol.2008.08.003.
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52, http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2.
37. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2007;176(7):706-12, http://dx.doi.org/10.1164/rccm.200703-500OC.
38. Trombetta IC, Somers VK, Maki-Nunes C, Drager LF, Toschi-Dias E, Alves MJ, et al. Consequences of comorbid sleep apnea in the metabolic syndrome-implications for cardiovascular risk. Sleep. 2010;33(9):1193-9.
39. Drager LF, Lopes HF, Maki-Nunes C, Trombetta IC, Toschi-Dias E, Alves MJ, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One. 2010;5(8):e12065, http://dx.doi.org/10.1371/journal.pone.0012065.
40. Drager LF, Bortolotto LA, Figueiredo AC, Silva BC, Krieger EM, Lorenzi-Filho G. Obstructive sleep apnea, hypertension, and their interaction on arterial stiffness and heart remodeling. Chest. 2007;131(5):1379-86, http://dx.doi.org/10.1378/chest.06-2703.
41. Wofford MR, Anderson DC, Jr., Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alphaand beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7 Pt 1):694-8.
42. Witkowski A, Prejbisz A, Florczak E, Kdziela J, Liwiński P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559-65.
43. Drager LF, Bortolotto LA, Maki-Nunes C, Trombetta IC, Alves MJ, Fraga RF, et al. The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome. Atherosclerosis. 2010;208(2):490-5, http://dx.doi.org/10.1016/j.atherosclerosis.2009.08.016.
44. Wofford MR, Anderson DC Jr., Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alphaand beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7 Pt 1):694-8.
45. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559-65, http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.173799.